Trump signs order to expand psychedelic therapy
SkimNews Take
The GOP's embrace of psychedelics, while a departure from historical drug policy, may reflect a broader trend of prioritizing individual mental health interventions over more complex, systemic social support structures for recovery.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump signed an executive order on Saturday to expand access to psychedelic therapies for mental health treatment.
- Rick Perry championed ibogaine in a Washington Post op‑ed, urging bipartisan funding for research.
- Dan Crenshaw introduced legislation directing the Department of Defense and the Department of Veterans Affairs to study psychedelics for PTSD and addiction.
- Texas allocated tens of millions of dollars for ibogaine research initiatives.
- New York Times ran a front‑page story on Perry’s ibogaine experience, framing him as a leader in the psychedelic revival.
Why it matters: Veterans and patients with PTSD gain federal research funding and expanded treatment options, while the GOP’s drug‑policy stance shifts toward medicalization, driving a multi‑million‑dollar surge in psychedelic R&D.
